While low-protein diets may reduce glomerular pressure and slow kidney damage by preventing the physiologic hyperfiltration that follows dietary protein intake (mediated by afferent arteriolar vasodilatation), pharmacological treatments such as angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin-II receptor blockers (ARBs), and sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors or flozins) achieve similar, if not superior, effects by dilating both the afferent and efferent arterioles (see Figure 2)26,27. This evidence concerns the gene SLC5A2 and Nephropathy.